Thyroid assessment and optimisation

Two claims must be separated. First, testing and treating genuine thyroid disease is established standard of care with decades of clinical evidence, and thyroid panels are ordinary pathology, not a longevity innovation. Second, the "optimisation" claim, treating euthyroid or subclinically hypothyroid people to feel better or age slower, is not supported. The TRUST randomised, double-blind, placebo-controlled trial (737 adults aged 65+ with persistent subclinical hypothyroidism, NEJM 2017) found no benefit of levothyroxine on hypothyroid symptoms or tiredness scores, and pooled analysis with a second RCT found no cardiovascular benefit. An ancillary TRUST analysis found no effect on depressive symptoms. AACE/ATA guidance explicitly states thyroid hormone should not be used to treat obesity in euthyroid patients, nor for depression. No RCT shows that pushing thyroid hormone within the normal range extends healthspan, improves body composition durably, or reduces mortality. Known harms of over-replacement are real and dose-dependent: Singapore's HSA has issued a safety communication on levothyroxine and fracture risk, and long-term suppressive dosing is associated with reduced bone mineral density and atrial fibrillation risk. IMPORTANT UNVERIFIED CLAIM: I confirmed that clinics in both markets include thyroid markers in longevity panels, but I could not verify from any clinic's own site that they prescribe thyroid hormone for optimisation in euthyroid patients. Treat the treatment side as unverified. Net position: the assessment is legitimate and cheap; the optimisation narrative is a commercial construct that the best available human RCT evidence contradicts.

What it is

Plain-language explainer

Categories

Common questions

What is Thyroid assessment and optimisation?

Two claims must be separated. First, testing and treating genuine thyroid disease is established standard of care with decades of clinical evidence, and thyroid panels are ordinary pathology, not a longevity innovation. Second, the "optimisation" claim, treating euthyroid or subclinically hypothyroid people to feel better or age slower, is not supported. The TRUST randomised, double-blind, placebo-controlled trial (737 adults aged 65+ with persistent subclinical hypothyroidism, NEJM 2017) found no benefit of levothyroxine on hypothyroid symptoms or tiredness scores, and pooled analysis with a second RCT found no cardiovascular benefit. An ancillary TRUST analysis found no effect on depressive symptoms. AACE/ATA guidance explicitly states thyroid hormone should not be used to treat obesity in euthyroid patients, nor for depression. No RCT shows that pushing thyroid hormone within the normal range extends healthspan, improves body composition durably, or reduces mortality. Known harms of over-replacement are real and dose-dependent: Singapore's HSA has issued a safety communication on levothyroxine and fracture risk, and long-term suppressive dosing is associated with reduced bone mineral density and atrial fibrillation risk. IMPORTANT UNVERIFIED CLAIM: I confirmed that clinics in both markets include thyroid markers in longevity panels, but I could not verify from any clinic's own site that they prescribe thyroid hormone for optimisation in euthyroid patients. Treat the treatment side as unverified. Net position: the assessment is legitimate and cheap; the optimisation narrative is a commercial construct that the best available human RCT evidence contradicts.

How strong is the evidence for Thyroid assessment and optimisation?

Clinical. There is human trial evidence, which is the strongest grade variis applies to a protocol.

Is Thyroid assessment and optimisation approved in Singapore?

Health Sciences Authority position on record: Levothyroxine is HSA-registered and available in Singapore as a prescription-only medicine, for example ELTROXIN tablet 50mcg (registration SIN13252P) and 100mcg (SIN13251P), indicated for hypothyroidism, benign euthyroid goitre and prophylaxis of relapse after goitre surgery, concomitant therapy during anti-thyroid treatment, and TSH suppression in thyroid cancer. HSA has issued a Dear Healthcare Professional letter on switching between Euthyrox formulations and a safety alert on levothyroxine and potential fracture risk, with package inserts strengthened on bone resorption and reduced bone mineral density. Liothyronine (T3) is not available through community or retail pharmacies in Singapore and is accessible only via prescription within selected healthcare institutions. Thyroid function blood tests are ordinary clinical pathology and require no HSA product approval. There is no registered indication in Singapore for thyroid hormone "optimisation" in euthyroid people; any such use would be off-label prescribing outside the approved indications.. An evidence grade and a regulatory approval are different questions.

Is Thyroid assessment and optimisation approved in Australia?

Therapeutic Goods Administration position on record: Levothyroxine is TGA-registered and listed on the ARTG under multiple brands (LEVOXINE, THYROX, LEVOTHYROXINE SANDOZ, LEVOTHYROXINE INTAS, among others), indicated for the management of demonstrated thyroid hormone deficiency and for TSH suppression in the management of TSH-responsive thyroid tumours. Liothyronine (T3) products are not registered on the ARTG for general use and are accessed as unapproved therapeutic goods, for example via the TGA Special Access Scheme (intravenous liothyronine such as Thyrotardin or Triostat-R is documented as obtainable through SAS), or through an Authorised Prescriber pathway. Thyroid function blood tests are standard pathology and are not TGA-regulated as therapeutic goods. No TGA-registered indication exists for thyroid hormone use in euthyroid patients for energy, weight or longevity purposes; that use would be off-label and, for T3 specifically, would additionally require an unapproved-goods pathway.. An evidence grade and a regulatory approval are different questions.

Which clinics offer Thyroid assessment and optimisation?

3 clinics in the variis directory across Singapore and Australia have Thyroid assessment and optimisation on record. Each is listed on this page with its own sourced profile.

What else is Thyroid assessment and optimisation called?

Also known as Thyroid optimisation, TSH/T3/T4 panel, Thyroid function testing, Thyroid hormone replacement, Levothyroxine (T4), Liothyronine (T3).